- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01770080
Efficacy of Euminz® for Tension-Type Headache (CAS/B/016611)
Efficacy and Safety of Euminz® (10% Ethanolic Solution of Peppermint Oil for Topical Use) Compared to Placebo in Patients With Episodic Tension-type Headache (ETTH); Phase IV Clinical Trial
Efficacy and safety of Euminz® (10% ethanolic solution of peppermint oil for topical use) compared to placebo in patients with episodic tension-type headache (ETTH).
Prospective, double-blind, placebo-controlled, phase IV clinical trial; Parallel-groups design; Randomisation 1:1; First attack per patient will be evaluated for primary objectives, following attacks during study duration will be observed and documented.
Study duration per patient: 10 weeks
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To demonstrate the efficacy of Euminz® to reduce the intensity of headache symptoms experienced by patients with episodic tension-type headache. The two primary objectives will be tested hierarchically (a-priory ordered) to avoid alpha-adjustment:
First primary objective of the first headache episode is "pain-free" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS). Acute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
Second primary objective of the first headache episode will be the decrease of intensity of pain measured by a visual analogue scale (VAS). The difference from measure point 0 (before first application of Euminz®) on the VAS in comparison to 15, 30, 45, 60, 90 and 120 minutes after start of treatment will be shown as area under the curve representing the pain intensity difference (PID).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 14109
- Charité, Chair of Complementary and Integrative Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients from 18 years onwards
- History of ETTH for at least one year. The number of days with such a headache is ≥2 per month
- Onset of TTH below 65 years of age
- At least 10 previous headache attacks fulfilling the following four inclusion criteria:
- Patients with headache attacks lasting from 30 minutes to 7 days
- At least two of the following pain characteristics are present:
- - Pressing or tightening (non-pulsating) quality
- - Intensity of pain: moderate = unable to ignore (pain may inhibit, but does not prohibit activities)
- - Bilateral location
- - No aggravation by walking stairs or similar routine physical activity
- Headache is not accompanied by nausea or vomiting (anorexia may occur)
- Headache is not accompanied by a combination of the following symptoms: photophobia and phonophobia (only one may be present)
- 3 months retrospective history
- Willingness and ability to keep the patient's diary and to comply with the procedures of the study
- Written informed consent
Exclusion Criteria:
- Headaches other than TTH: (e.g. migraine, cluster headache, hypertension headache, drug-related headache,analgesic-induced headache,post-traumatic headache; associated migraine attacks are permitted if they are well recognized by the patient and if their frequency during the preceding year has not exceeded one per month)
- Presence of oromandibular dysfunction
- History of facial or cranial surgery
- Use of prophylactic drugs for headache within one month prior to enrolment
- Use of drugs for acute TTH treatment for ≥ 10 days of headache per month
- Anticipated problems in adhering to the self-observation procedure (e.g. because of work)
- Abuse of alcohol, narcotics or other drugs
- Serious illnesses within the last 3 months (e.g. myocardial infarction, cardiac insufficiency NYHA III and IV, low blood pressure, cerebral insult, diabetes mellitus, neuropathy, changes in the skin or neoplasms in the head)
- Epilepsy
- Intake of anti-psychotic, anti-depressant or anti-epileptic medication during the previous month
- Intake of long-acting non-steroidal anti-inflammatory drugs within the last month
- Planned start of new pharmacological or non-pharmacological therapies
- Any significant skin condition affecting face or neck
- Known hypersensitivity towards peppermint oil
- Previous use of Euminz® or any other essential oil solutions for headache in the last three months
- Participation in another clinical trial within the last month
- Accommodation in an institution at judicial or official request
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Euminz®
Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
|
3 to 5 time topical use of study drug.
Other Names:
|
Placebo Comparator: Placebo
Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
|
3 to 5 time topical use of study drug.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First primary objective of the first headache episode is "pain-free" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS).
Time Frame: 2 hours
|
Acute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
|
2 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Further headache attacks will be documented and evaluated during study duration (VPRS, VAS) and described as sum of pain intensity differences (SPID)
Time Frame: 10 weeks
|
10 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 48 hours
|
Physical eximanations, overall assessments both by the patients and the investigator, vital signs, adverse events.
|
48 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Yatin Shah, MD, Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Headache
- Tension-Type Headache
- Physiological Effects of Drugs
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Peppermint oil
- Pharmaceutical Solutions
Other Study ID Numbers
- 2011-004777-89
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Episodic Tension-Type Headache
-
Lucia Trullenque EspallargasNot yet recruitingChronic Tension-Type Headache | Episodic Tension-Type HeadacheSpain
-
NMP Medical Research InstituteCompleted
-
Azidus BrasilUnknownTreatment of Episodic Tension HeadacheBrazil
-
Iran University of Medical SciencesNot yet recruitingEpisodic Tension-type Headache
-
BayerCompletedHeadache | Tension-Type Headache | Tension-Type Headache (Episodic)United Kingdom
-
Poitiers University HospitalRecruitingTension-Type Headache EpisodicFrance
-
Grand Valley State UniversityMary Free Bed Rehabilitation HospitalCompletedHeadaches, TensionUnited States
-
University of ValenciaCompletedTension-type HeadacheSpain
-
Riphah International UniversityCompletedTension Type HeadachePakistan
-
University of ValenciaCompleted
Clinical Trials on Euminz®
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States